In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.

Latest From Ramsey Baghdadi

The Gene Therapy Wave Is Here

The long-talked about wave of gene therapy approvals is beginning to reveal itself.

Gene Therapy Review Pathway

Will The Excise Tax Torpedo The IRA Drug Price Negotiation Program?

A case involving a tax that was an “exceedingly heavy burden” and played into the Supreme Court’s original ruling on the ACA could reemerge once the IRA challenge reaches the high court.

Pricing Debate Legal Issues

Using A Natural History Study As An External Control In Rare Diseases: Ipsen Offers An Example

Although the advisory committee was uncomfortable with the external control, US FDA was reassuring over the approach – which eventually secured a ‘yes’ vote from the panel on palovarotene for FOP.

Advisory Committees Rare Diseases

Artificial Intelligence Legislative Activity To Start In Fall; Sen. Schumer Lays Out Principles, Process

As US FDA offers initial issues for industry consideration, Senate majority leader outlines framework and process of a bipartisan effort to construct the ‘first of its kind’ legislation to regulate AI.

Digital Health Legislation

Patient-Focused Drug Negotiation? CMS Revised Guidance Says Listening Sessions To Begin This Fall

Patient input meeting will be an added element to the Medicare Drug Price Negotiation Program.

Government Payers Medicare

The Greatest FDA Advisory Committees Of All Time Part IV: Neurology Lays Claim To The Crown

We look back at another of the greatest FDA advisory committees of the last 20 years. This time: the nearly 12-hour meeting in 2016 on Sarepta’s eteplirsen for Duchenne muscular dystrophy.

Advisory Committees Drug Review
See All